Liane Rae Teplitsky Buys 1,036 Shares of Pulse Biosciences (NASDAQ:PLSE) Stock

Pulse Biosciences, Inc (NASDAQ:PLSE) COO Liane Rae Teplitsky purchased 1,036 shares of the business’s stock in a transaction dated Wednesday, August 26th. The shares were acquired at an average cost of $48.23 per share, for a total transaction of $49,966.28. Following the acquisition, the chief operating officer owned 1,036 shares of the company’s stock, valued at approximately $49,966.28. The trade was a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Liane Rae Teplitsky also recently made the following trade(s):

• On Friday, August 28th, Liane Rae Teplitsky purchased 1,034 shares of Pulse Biosciences stock. The shares were acquired at an average cost of $48.35 per share, for a total transaction of $49,993.90.

Pulse Biosciences Trading Down 2.0%

Pulse Biosciences stock opened at $47.57 on Friday. The stock has a market cap of $3.29 billion, a price-to-earnings ratio of -40.31 and a beta of 1.61. The company’s 50-day moving average price is $35.38 and its two-hundred day moving average price is $27.00. Pulse Biosciences, Inc has a 52 week low of $12.56 and a 52 week high of $50.90.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. The firm had revenue of $0.43 million for the quarter, compared to the consensus estimate of $0.53 million. Research analysts expect that Pulse Biosciences, Inc will post -1.29 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Needham & Company LLC initiated coverage on shares of Pulse Biosciences in a research note on Monday, August 17th. They set a “buy” rating and a $58.00 target price on the stock. Mizuho set a $45.00 target price on Pulse Biosciences in a report on Monday, August 10th. Oppenheimer reaffirmed an “outperform” rating on shares of Pulse Biosciences in a research report on Tuesday, July 28th. Finally, Wall Street Zen upgraded Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Saturday. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $45.25.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. BlackRock Inc. bought a new stake in Pulse Biosciences in the second quarter worth $40,672,000. Bank of America Corp DE bought a new position in Pulse Biosciences during the second quarter valued at about $40,115,000. California State Teachers Retirement System lifted its position in shares of Pulse Biosciences by 2,600.0% in the second quarter. California State Teachers Retirement System now owns 567,883 shares of the company’s stock worth $15,747,000 after buying an additional 546,850 shares during the last quarter. State Street Corp boosted its stake in shares of Pulse Biosciences by 6.0% during the 4th quarter. State Street Corp now owns 447,067 shares of the company’s stock worth $6,138,000 after acquiring an additional 25,187 shares in the last quarter. Finally, Brooklyn Investment Group boosted its stake in shares of Pulse Biosciences by 330.7% during the 4th quarter. Brooklyn Investment Group now owns 130,340 shares of the company’s stock worth $1,844,000 after acquiring an additional 100,081 shares in the last quarter. Institutional investors and hedge funds own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.